ArticleJournal of Cancer2023
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study.
Open access · goldAbstract read
In one paragraph
Article in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 11 citations in OpenAlex.
- Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial.International journal of cancer · 2026Trial
- Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.Cancer research and treatment · 2024Trial
- Delayed and long-delayed chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a scoping review of reporting gaps.ESMO open · 2026Review
- Article
- Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies.The oncologist · 2025Article
- Strategies to enhance management of HER2-positive breast cancer in the elderly: an expert consensus perspective.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.Future oncology (London, England) · 2025Review
- Management of nausea and vomiting induced by antibody-drug conjugates.Breast cancer (Tokyo, Japan) · 2025Review
- MASCC antiemetic consensus recommendations: resource-limited settings.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice.Frontiers in oncology · 2024Article
- Disproportionality Analysis of Gastrointestinal Adverse Events Associated With Trastuzumab Deruxtecan Using the Japanese Adverse Drug Event Report database.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 18 institutions in 1 country.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
Hiroko BandoInstitute of Medicine, Breast and Endocrine Surgery, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Yoshimi NiwaDepartment of Breast Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Yutaka MizunoDepartment of Breast Surgery, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi, Mie 510-8567, Japan.
Yoshihiro KawaguchiDepartment of Breast Surgery, Asahi University Hospital, 3-23 Hashimoto-cho, Gifu, Gifu 500-8523, Japan.
Mika KitahoraDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Akari MurakamiDepartment of Breast Center, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791-0295, Japan.
Masaaki KawaiDepartment of Breast Surgery, Miyagi Cancer Center, 47-1 Aza-nodayama, Medeshima-shiote, Natori, Miyagi 981-1239, Japan.
Kazushige IshidaDepartment of Surgery, Iwate Medical University, 2-1-1 Idaidori, Yahaba, Shiwa, Iwate 028-3695, Japan.
Makoto TakeuchiDepartment of Breast Surgery, Central Japan International Medical Hospital, 1-1 Kenkonomachi, Minokamo, Gifu 505-8510, Japan.
Kazuhiro IshiharaDepartment of Surgery, Gihoku Kosei Hospital, 1187-3 Takatomi, Yamagata, Gifu 501-2105, Japan.
Tomokazu IyodaDepartment of Pharmacy, Fukushima Medical University Hospital, 1 Hikariga-oka, Fukushima 960-1247, Japan.
Takumi NakadaDepartment of Breast Surgery, Gifu Municipal hospital, 7-1 Kashimacho, Gifu, Gifu 500-8513, Japan.
Atsuko OgisoDepartment of Breast Surgery, Gifu Prefectural General Medical Center, 4-6-1 Noishiki, Gifu, Gifu 500-8717, Japan.
Yasuyuki KojimaDepartment of Breast and Endocrine Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae, Kawasaki, Kanagawa 216-8511, Japan.
Fumiyoshi KumagaiDepartment of Pharmacy, Tohoku Rosai Hospital, 4-3-21 Dainohara, Miyagino, Sendai, Miyagi 981-8563, Japan.
Aya SawaDepartment of breast, thyroid, endocrine surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan.
Ryutaro MoriDepartment of Breast Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Kosuke HiguchiDepartment of Pharmacy, Yokkaichi Municipal Hospital, 2-2-37 Shibata, Yokkaichi, Mie 510-8567, Japan.
Tomoko FurutaDepartment of Pharmacy, Asahi University Hospital, 3-23 Hashimoto-cho, Gifu, Gifu 500-8523, Japan.
Yoshiaki KameiDepartment of Breast Center, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791-0295, Japan.
Masami TsuchiyaDepartment of Pharmacy, Miyagi Cancer Center, 47-1 Nodayama, Medeshimashiote, Natori, Miyagi 981-1293, Japan.
Azusa TerasakiDepartment of breast, thyroid, endocrine surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan.
Senri YamamotoDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Mai KitazawaDepartment of Breast Surgery, Asahi University Hospital, 3-23 Hashimoto-cho, Gifu, Gifu 500-8523, Japan.
Mai OkazakiDepartment of breast, thyroid, endocrine surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki 305-8576, Japan.
Akio SuzukiDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Manabu FutamuraDepartment of Breast Surgery, Gifu University Hospital, 1-1 Yanagido, Gifu, Gifu 501-1194, Japan.
Gifu University Hospital · JPUniversity of Tsukuba Hospital · JPEhime University Hospital · JPYokkaichi Municipal Hospital · JPAsahi University · JPFukushima Medical University Hospital · JPGifu Municipal Hospital · JPGifu Pharmaceutical University · JPGifu Prefectural General Medical Center · JPIwate Medical University · JPKihoku hospital · JPMiyagi Prefectural Hospital Organization · JPNational Hospital Organization Kyushu Cancer Center · JPSaitama International Medical Center · JPSt. Marianna University School of Medicine · JPTohoku Rosai Hospital · JPUniversity of Tsukuba · JPYamagata University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
antiemetic regimenbreast cancernauseatrastuzumab deruxtecanvomiting
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.